AIM: To evaluate the effect of the natural diterpenoid, hypoestoxide (HE) on the growth of established colon cancer in mice. METHODS: The CT26.WT mouse colon carcinoma cell line was grown and expanded in vitro. Following the expansion, BALB/c mice were inoculated s.c. with viable tumor cells. After the tumors had established and developed to about 80-90 mm(3), the mice were started on chemotherapy by oral administration of HE, 5-fluorouracil (5-FU) or combination. RESULTS: The antiangiogenic HE has previously been shown to inhibit the growth of melanoma in the B16F(1) tumor model in C57BL/6 mice. Our results demonstrate that mean volume of tumors in mice treated with oral HE as a single agent or in combination with 5-FU, were significantly smaller (> 60%) than those in vehicle control mice (471.2 mm(3) vs 1542.8 mm(3), P < 0.01). The significant reductions in tumor burden resulted in pronounced mean survival times (MST) and increased life spans (ILS) in the treated mice. CONCLUSION: These results indicate that HE is an effective chemotherapeutic agent for colorectal cancer in mice and that HE may be used alone or in combination with 5-FU.
AIM: To evaluate the effect of the natural diterpenoid, hypoestoxide (HE) on the growth of established colon cancer in mice. METHODS: The CT26.WT mousecolon carcinoma cell line was grown and expanded in vitro. Following the expansion, BALB/c mice were inoculated s.c. with viable tumor cells. After the tumors had established and developed to about 80-90 mm(3), the mice were started on chemotherapy by oral administration of HE, 5-fluorouracil (5-FU) or combination. RESULTS: The antiangiogenic HE has previously been shown to inhibit the growth of melanoma in the B16F(1) tumor model in C57BL/6 mice. Our results demonstrate that mean volume of tumors in mice treated with oral HE as a single agent or in combination with 5-FU, were significantly smaller (> 60%) than those in vehicle control mice (471.2 mm(3) vs 1542.8 mm(3), P < 0.01). The significant reductions in tumor burden resulted in pronounced mean survival times (MST) and increased life spans (ILS) in the treated mice. CONCLUSION: These results indicate that HE is an effective chemotherapeutic agent for colorectal cancer in mice and that HE may be used alone or in combination with 5-FU.
Authors: E A Ojo-Amaize; P Kapahi; V N Kakkanaiah; T Takahashi; T Shalom-Barak; H B Cottam; A A Adesomoju; E J Nchekwube; O A Oyemade; M Karin; J I Okogun Journal: Cell Immunol Date: 2001-05-01 Impact factor: 4.868
Authors: S Flis; D Soltysiak-Pawluczuk; A Jedrych; Z Jastrzebski; M Remiszewska; J Splawinski Journal: Anticancer Res Date: 2006 Jul-Aug Impact factor: 2.480
Authors: Kenji Yokoi; Premal H Thaker; Sertac Yazici; Robert R Rebhun; Do-Hyun Nam; Junqin He; Sun-Jin Kim; James L Abbruzzese; Stanley R Hamilton; Isaiah J Fidler Journal: Cancer Res Date: 2005-05-01 Impact factor: 12.701
Authors: Emmanuel A Ojo-Amaize; Emeka J Nchekwube; Howard B Cottam; Ruoli Bai; Pascal Verdier-Pinard; Vellalore N Kakkanaiah; Judith A Varner; Lorenzo Leoni; Joseph I Okogun; Akinbo A Adesomoju; Olusola A Oyemade; Ernest Hamel Journal: Cancer Res Date: 2002-07-15 Impact factor: 12.701
Authors: Sarbjeet Makkar; Terrence E Riehl; Baosheng Chen; Yan Yan; David M Alvarado; Matthew A Ciorba; William F Stenson Journal: Mol Cancer Ther Date: 2019-09-04 Impact factor: 6.261